Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
09 2023
Historique:
received: 13 07 2023
accepted: 14 07 2023
pmc-release: 01 09 2024
medline: 18 8 2023
pubmed: 3 8 2023
entrez: 3 8 2023
Statut: ppublish

Résumé

Tumors of the central nervous system (CNS) are a leading cause of morbidity and mortality in the pediatric population. Molecular characterization in the last decade has redefined CNS tumor diagnoses and risk stratification; confirmed the unique biology of pediatric tumors as distinct entities from tumors that occur in adulthood; and led to the first novel targeted therapies receiving Food and Drug Administration (FDA) approval for children with CNS tumors. There remain significant challenges to overcome: children with unresectable low-grade glioma may require multiple prolonged courses of therapy affecting quality of life; children with high-grade glioma have a dismal long-term prognosis; children with medulloblastoma may suffer significant short- and long-term morbidity from multimodal cytotoxic therapy, and approaches to improve survival in ependymoma remain elusive. The Children's Oncology Group (COG) is uniquely positioned to conduct the next generation of practice-changing clinical trials through rapid prospective molecular characterization and therapy evaluation in well-defined clinical and molecular groups.

Identifiants

pubmed: 37534382
doi: 10.1002/pbc.30600
pmc: PMC10569820
mid: NIHMS1930175
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e30600

Subventions

Organisme : NCI NIH HHS
ID : U24 CA196173
Pays : United States
Organisme : NIH HHS
ID : U10CA098543
Pays : United States
Organisme : NIH HHS
ID : U24CA114766
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098543
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098413
Pays : United States
Organisme : NIH HHS
ID : U10CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA114766
Pays : United States
Organisme : NIH HHS
ID : U24CA196173
Pays : United States
Organisme : NIH HHS
ID : U10CA098413
Pays : United States

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Lancet Oncol. 2015 May;16(5):569-82
pubmed: 25882982
Neurooncol Adv. 2021 Jul 07;3(1):vdab097
pubmed: 34409296
J Clin Oncol. 2021 Aug 20;39(24):2685-2697
pubmed: 34110925
Childs Nerv Syst. 2009 Oct;25(10):1261-8
pubmed: 19373477
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Clin Cancer Res. 2023 May 1;:
pubmed: 37126021
Neuro Oncol. 2021 Oct 1;23(10):1777-1788
pubmed: 33631016
J Clin Oncol. 2012 Jul 20;30(21):2648-53
pubmed: 22665539
Qual Life Res. 2018 Feb;27(2):529-537
pubmed: 29090422
Ann Oncol. 2015 Mar;26(3):589-97
pubmed: 25527416
Acta Neuropathol. 2018 Aug;136(2):227-237
pubmed: 30019219
J Pediatr Hematol Oncol. 2019 Aug;41(6):433-437
pubmed: 30629003
Neuro Oncol. 2012 Sep;14(9):1194-200
pubmed: 22869621
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
Neoplasia. 2023 Feb;36:100860
pubmed: 36521378
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
J Clin Oncol. 2020 Apr 10;38(11):1175-1185
pubmed: 32105509
Pediatr Blood Cancer. 2013 Jun;60(6):1022-6
pubmed: 23255213
Eur J Cancer. 2012 Jan;48(2):263-9
pubmed: 22206862
Neuro Oncol. 2022 Jun 1;24(6):974-983
pubmed: 34850169
Acta Neuropathol. 2022 Jun;143(6):697-711
pubmed: 35501487
Neuro Oncol. 2018 Jan 22;20(2):160-173
pubmed: 29016845
Lancet Oncol. 2018 Dec;19(12):1602-1616
pubmed: 30392813
Acta Neuropathol. 2017 Jan;133(1):5-12
pubmed: 27858204
Neuro Oncol. 2020 Oct 14;22(10):1536-1544
pubmed: 32215549
Acta Neuropathol. 2014 Jul;128(1):137-49
pubmed: 24791927
Brain Pathol. 2021 Sep;31(5):e12967
pubmed: 33938067
Semin Oncol. 2020 Feb;47(1):8-22
pubmed: 32139101
Oncologist. 2008 Jun;13(6):690-9
pubmed: 18586924
J Clin Oncol. 2021 Mar 1;39(7):822-835
pubmed: 33405951
J Clin Oncol. 2014 Mar 20;32(9):886-96
pubmed: 24493713
JAMA Oncol. 2021 Sep 01;7(9):1313-1321
pubmed: 34292305
Nat Med. 2023 May;29(5):1103-1112
pubmed: 37059834
Neurotherapeutics. 2022 Oct;19(6):1733-1751
pubmed: 35859223
Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):143-151
pubmed: 34990779
J Clin Oncol. 2020 Jan 20;38(3):223-231
pubmed: 31774708
J Clin Oncol. 2015 Aug 1;33(22):2464-71
pubmed: 26101244
Neuro Oncol. 2016 Oct;18(10):1442-50
pubmed: 27006176
Acta Neuropathol. 2017 Nov;134(5):705-714
pubmed: 28733933
J Clin Oncol. 2019 Dec 10;37(35):3335-3339
pubmed: 31498029
Clin Cancer Res. 2021 May 15;27(10):2879-2889
pubmed: 33737307
Neuro Oncol. 2017 Jun 1;19(6):750-761
pubmed: 27683733
Nature. 2014 Feb 27;506(7489):451-5
pubmed: 24553141
Cancer Radiother. 2019 Sep;23(5):370-377
pubmed: 31331843
J Clin Oncol. 2019 Dec 1;37(34):3283-3290
pubmed: 31545689
Neuro Oncol. 2022 Apr 1;24(4):655-664
pubmed: 34347089
Neuro Oncol. 2022 Jul 1;24(7):1178-1190
pubmed: 34935967
Neuro Oncol. 2011 Apr;13(4):410-6
pubmed: 21345842
Pediatr Blood Cancer. 2017 Sep;64(9):
pubmed: 28296130
Neuro Oncol. 2018 Jan 10;20(1):13-23
pubmed: 28449033
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Pediatr Blood Cancer. 2023 Jun;70 Suppl 4:e30147
pubmed: 36519599
BMC Cancer. 2019 Jun 11;19(1):571
pubmed: 31185958
Curr Opin Pediatr. 2019 Feb;31(1):21-27
pubmed: 30531227
Cancer. 2016 Jun 15;122(12):1928-36
pubmed: 27061921
J Clin Oncol. 2015 Aug 20;33(24):2646-54
pubmed: 26169613
J Clin Oncol. 2018 Oct 17;:JCO2017764720
pubmed: 30332335
J Clin Oncol. 2012 Jul 20;30(21):2641-7
pubmed: 22665535
J Neurooncol. 2020 Oct;150(1):47-56
pubmed: 33021733
Acta Neuropathol. 2019 Dec;138(6):1075-1089
pubmed: 31414211
Nat Commun. 2019 Sep 25;10(1):4343
pubmed: 31554817
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Cell. 2016 Mar 14;29(3):379-393
pubmed: 26923874
Neuro Oncol. 2022 Sep 6;24(Suppl 3):iii1-iii38
pubmed: 36066969
J Clin Oncol. 2019 Apr 20;37(12):974-983
pubmed: 30811284
J Clin Oncol. 2006 Sep 1;24(25):4202-8
pubmed: 16943538
Neuro Oncol. 2011 Mar;13(3):317-23
pubmed: 21339192
Pediatr Blood Cancer. 2011 Dec 1;57(6):978-85
pubmed: 21796761
J Clin Oncol. 2016 Oct 10;34(29):3537-3543
pubmed: 27573663
Neoplasia. 2023 May;39:100898
pubmed: 37011459
Cancer Cell. 2016 Dec 12;30(6):891-908
pubmed: 27960086
Neuro Oncol. 2020 Jul 7;22(7):1006-1017
pubmed: 31883020

Auteurs

Sarah E S Leary (SES)

Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, Seattle, Washington, USA.

Arzu Onar-Thomas (A)

Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Jason Fangusaro (J)

Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.

Nicholas G Gottardo (NG)

Telethon Kids Cancer Centre, University of Western Australia, Perth, Western Australia, Australia.

Kenneth Cohen (K)

The Sidney Kimmel Comprehensive Cancer Center, John's Hopkins, Baltimore, Maryland, USA.

Amy Smith (A)

Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, Orlando Health-Arnold Palmer Hospital, Orlando, Florida, USA.

Annie Huang (A)

Department of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.

Daphne Haas-Kogan (D)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Maryam Fouladi (M)

Division of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio, USA.
Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH